Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
22nd December 2020 | Jay Venkatesan | 181,024 | Other acquisition or disposition | $0.00 | |
22nd December 2020 | Jay Venkatesan | 993,801 | Other acquisition or disposition | $0.00 | |
14th October 2020 | Bali Muralidhar | 200,000 | Open or private purchase | $15.00 | $3,000,000.00 |
14th October 2020 | Bali Muralidhar | 1,592,518 | Conversion of derivative | $0.00 | |
6th July 2020 | Jay Venkatesan | 9,310 | Exercise of derivative | $0.65 | $6,051.50 |
6th July 2020 | Jay Venkatesan | 12,930 | Exercise of derivative | $1.03 | $13,317.90 |
12th June 2020 | Llc Aurasense | 10,195 | Open or private sale | $2.83 | $28,851.85 |
12th June 2020 | Chad A. Mirkin | 10,195 | Open or private sale | $2.83 | $28,851.85 |
20th May 2020 | Chad A. Mirkin | 49,649 | Exercise of derivative | $0.65 | $32,271.85 |
13th March 2020 | David R Walt | 291,066 | Open or private purchase | $1.21 | $352,859.31 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Exicure, Inc. engages in the provision of clinical stage biotechnology company. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
8th March 2021
7th March 2021